On November 5, 2026, the clinical trial registry listed an update for a study involving thymosin beta-4. The trial, titled "Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2," is registered under identifier NCT05555589.
The study is a Phase 3 trial evaluating the 0.1% RGN-259 ophthalmic solution for neurotrophic keratopathy, abbreviated as NK. According to the registry entry, the trial status is now listed as completed.
Thymosin beta-4 remains classified as an unapproved compound under current regulatory status, meaning it has not received approval for the indication studied in this trial or for general use. This update reflects only a change in the trial's listed status on the registry.
No results, efficacy data, or safety outcomes were included in this status update. The completion designation indicates the trial has concluded its planned activities, but it does not by itself confirm any particular finding. Readers interested in the specific data from this study should consult the official registry listing for further detail as it becomes available.
For more background on this compound, readers can refer to the linked compound overview.